CBD drugmaker GW Pharmaceuticals poised to raise $300 million

On: October 2, 2018

GW Pharmaceuticals is setting out to sell $300 million worth of U.S. depository shares. The London-based company’s announcement comes on the heels of the U.S. Drug Enforcement Administration’s move to take some cannabidiol products off the most restrictive class of controlled substances. That change will allow Epidiolex – a CBD drug manufactured by GW Pharmaceuticals to treat rare […]

CBD drugmaker GW Pharmaceuticals poised to raise $300 million is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs

Previous Post: Proposed tax in Phoenix could cost medical marijuana firms $1 million+ annually

Next Post: No Snoop for you! Celebrity names not allowed come cannabis legalization in Canada

Comments are closed, but trackbacks and pingbacks are open.